Pneumovax 23

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

LymphomaObesity

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

1

Pneumovax 23

GSK

Phase 3

12

Zofran

Novartis

Preclinical

23

Norvir

AbbVie

Preclinical

14

Cabenuva

GSK

Preclinical

15

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

16

Kenalog

BBausch Health Americas, Inc.

Preclinical

17

Nuvigil

NNuvo Research GmbH

Preclinical

18

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—Show 31 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Immunogenicity6 trials

Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3.

Completed·GGPN Vaccines·Phase 1·NCT05667740·118 enrolled

The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002)

Completed·Merck & Co.·Phase 2·NCT01513551·692 enrolled

A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018)

Completed·Merck & Co.·Phase 3·NCT01734239·102 enrolled

Show 3 more trials

Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029)

Completed·Merck & Co.·Phase 3·NCT02225587·400 enrolled

Extension Safety and Immunogenicity Study of GPNV-001

Completed·GGPN Vaccines·Phase 1/2·NCT05982314·60 enrolled

Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants

Completed·PPATH·Phase 1/2·NCT02308540·346 enrolled

Immunization2 trials

Persistent Readiness Through Early Prediction Immunization Study

Completed·TTexas A&M University·Phase 1·NCT05346302·249 enrolled

Pneumococcal Adult-dose Ranging Immunization Study

Completed·KKaiser Permanente·Phase 1/2·NCT00169234·220 enrolled

Vaccination2 trials

Pneumococcal Vaccination of Fiji Infants

Completed·UUniversity of Melbourne·Phase 2·NCT00170612·552 enrolled

Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902)

Completed·Merck & Co.·Phase 4·NCT02260882·243 enrolled

Immune Response2 trials

Immune Response to PNEUMOVAX 23 in Healthy Adults Receiving Efgartigimod IV

Completed·Argenx·Phase 1·NCT05163834·36 enrolled

The Effect of Short-term Atorvastatin Treatment on Immune Responses to Pneumovax 23

Completed·UUniversity of Florida·Phase 1·NCT02097589·33 enrolled

Obesity1 trial

Effect of Obesity on Immune Response to Pneumovax 23

Completed·UUniversity of Florida··NCT02471014·50 enrolled

9 more indications

Elderly1 trial

Study to Evaluate the Response Rate to the Licensed Pneumovax 23™ in Elderly Population.

Completed·GSK·Phase 2·NCT00307008·1,198 enrolled

Influenza1 trial

Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) When Co-administered With Pneumovax™ 23 in Adults 50 Years of Age and Older

Completed·GSK·Phase 3·NCT02218697·357 enrolled

Antibody Response1 trial

Polysaccharide Antibody Response Study

Completed·UUniversitaire Ziekenhuizen KU Leuven·Phase 4·NCT02429531·200 enrolled

Adult1 trial

A Protocol to Collect Human Serum Samples From Healthy Adults for Use as Quality Controls Samples in GlaxoSmithKline (GSK) Biologicals' Assays

Completed·GSK·Phase 4·NCT02072525·359 enrolled

Safety and Efficacy1 trial

Safety and Efficacy Study of Investigational Pneumococcal Vaccine in Elderly Population

Completed·GSK·Phase 2·NCT00307528·146 enrolled

Chemotherapy1 trial

Vaccinating Children After Chemotherapy

Completed·CCanadian Immunization Research Network·Phase 4·NCT02447718·156 enrolled

Asplenia1 trial

Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients

Recruiting·UUniversity of California, Davis·Phase 2·NCT02232191·75 enrolled

Lymphoma1 trial

Vaccine Responses in Patients With B Cell Malignancies

Recruiting·NNational Heart, Lung, and Blood Institute (NHLBI)·Approved·NCT05170399·350 enrolled

Unspecified1 trial

Pneumococcal Reference Standard

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00479323·250 enrolled

Details

Drug Info

Related News